AUTHORS
Jeddeo Paul, MD, MBA, Dilek Uzun, MD2, Sean Yeung3, Kristy Torrez4, Theresa Latchford5, Sally Arai, MD6, Vanessa E Kennedy, MD7, Sushma Bharadwaj, MD8, Parveen Shiraz, MD9, Wen-Kai Weng, MD, PhD10, Melody Smith, MD,MS11, Mathew J. Frank, MD, PhD12, Saurabh Dahiya, MD, FACP13, Hany Elmariah, MD,MS14, Laura Johnston, MD15, Andrew Rezvani, MD16, Judith Anne Shizuru, MD, PhD17, Robert Lowsky, MD18, Lori Muffly, MD19, David Miklos, MD, PhD20, David Iberri, MD21, Hyma Vempaty22, Emily C. Liang, MD23, Michaela Liedtke, MD24, Gary Goldstein25, Surbhi Sidana, MD26, Lekha Mikkilineni, MD, MA27
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States, Stanford University School of Medicine, Stanford, California, United States
2 San Joaquin General Hospital, San Joaquin, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Stanford Health Care, Palo Alto, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 Stanford University School of Medicine, Stanford, California, United States
8 Stanford University School of Medicine, Stanford, California, United States
9 Stanford University School of Medicine, Stanford, California, United States
10 Stanford University School of Medicine, Stanford, California, United States
11 Stanford University School of Medicine, Stanford, California, United States
12 Stanford University School of Medicine, Stanford, California, United States
13 Stanford University School of Medicine, Stanford, California, United States
14 Stanford University School of Medicine, Stanford, California, United States
15 Stanford University School of Medicine, Stanford, California, United States
16 Stanford University School of Medicine, Stanford, California, United States
17 Stanford University School of Medicine, Stanford, California, United States
18 Stanford University School of Medicine, Stanford, California, United States
19 Stanford University School of Medicine, Stanford, California, United States
20 Stanford University School of Medicine, Stanford, California, United States
21 Stanford University School of Medicine, Stanford, California, United States
22 Stanford University School of Medicine, Stanford, California, United States
23 Stanford University School of Medicine, Stanford, California, United States
24 Stanford University School of Medicine, Stanford, California, United States
25 Stanford University School of Medicine, Stanford, California, United States
26 Stanford University School of Medicine, Stanford, California, United States
27 Stanford University School of Medicine, Stanford, California, United States
ABSTRACT
Introduction
CAR-T and bispecific antibody (BsAb) therapies have transformed multiple myeloma (MM) treatment across early- and late-line relapse, yet real-world data comparing their total cost of care, particularly beyond the initial treatment period, remain scarce. To characterize both the magnitude and the timing of these costs, we conducted a single-institution, retrospective analysis of real-world costs following cilta-cel or BsAb therapy and modeled the time at which cumulative cilta-cel cost would fall below that of continuous BsAb therapy among patients (pts) who remain progression-free.
Methods
In this retrospective cohort analysis, we compared the total costs accrued over a 1-year episode in pts with relapsed or refractory MM receiving either ciltacabtagene autoleucel (cilta-cel) or BsAb therapy (teclistamab or talquetamab) at Stanford Health Care between July 2022 and January 2025. Episodes began at apheresis (or bridging start, if earlier) or first BsAb treatment, using institutional billing data (technical and professional charges). Charges were converted to costs based on an institution-wide cost-to-charge ratio of 17.85%, calculated from public hospital financial statements, and adjusted for inflation (Dec 2025 USD, PCE price index). Costs were assigned to 10 mutually exclusive categories and stratified by treatment phase relative to infusion date: pre/peri-treatment (episode start through day+7), short-term post-treatment (day+8-90) and long-term post-treatment (>day+90). BsAb doses both within and outside of Stanford were manually counted via chart review; because out-of-Stanford costs were not captured, a Stanford-only sensitivity analysis was performed in the subset with complete BsAb cost capture. Costs were compared using two-sided Mann-Whitney U (median, IQR). Category-level comparisons were unadjusted and exploratory. A break-even model projected observed monthly costs forward at a constant rate to estimate the cost parity between cilta-cel and BsAb, conditional on remaining progression-free, with 95% CIs from patient-level bootstrapping (10,000 resamples).
Results
We identified 109 episodes in 94 pts: 70 cilta-cel and 39 BsAb (24 tec, 15 tal). Sixteen (23%) cilta-cel pts received at least one BsAb therapy during the episode (14 for bridging and 2 for post-progression salvage), and 1 (2.6%) BsAb pt also received cilta-cel during the episode. BsAb pts received a mean 12.0 ± 10.6 doses at Stanford vs 4.9 ± 8.1 doses outside of Stanford, reflecting substantial outside hospital dosing.
Median total 1-year costs were higher for cilta-cel compared to BsAb ($826,293 vs $369,840, p<0.001). Pharmacy was the largest category for both ($639,471 vs $235,558, p<0.001), followed by inpatient care ($76,104 vs $49,010, p=0.06). By phase, cilta-cel costs were higher than BsAb costs pre/peri treatment ($719,051 vs $72,575, p<0.001) but lower short-term post-treatment ($72,938 vs $134,119, p=0.03) and trended toward lower long-term ($5,751 vs $79,925, p=0.15). Total costs showed similar trends in the Stanford-only BsAb episodes (n = 25, median $416,369). The subgroup of cilta-cel pts who received talquetamab-based bridging therapy incurred significantly higher median pre/peri-treatment costs than those who received non-BsAb bridging therapy ($890,554 vs $713,052, p<0.001).
To account for differential survival, we compared mean costs per patient month (mo): $88,327 (cilta-cel) vs $46,306 (BsAb) overall and $10,203 (cilta-cel) vs $32,770 (BsAb) in the long-term phase. Among pts treated exclusively at Stanford who remained progression-free at 1 year (cilta-cel, n=27: $6,401/mo; BsAb, n=6: $46,011/mo), projecting forward at the observed 19.3-day BsAb dosing interval, cumulative cilta-cel cost fell below BsAb after 1.64 years progression-free (95% CI 1.27 – 2.26). Across BsAb dosing assumptions, this ranged from 0.77 years (weekly) to 3.87 years (every 2 months).
Conclusion
Although cilta-cel incurred higher first-year costs, these were concentrated at or before treatment initiation, whereas BsAb costs accrued continuously thereafter. Cilta-cel pts requiring tal-bridging incurred the highest pre/peri-treatment costs, suggesting a potential economic rationale for earlier CAR-T when patients have less costly, alternative bridging options. Among durable responders, cumulative cilta-cel cost is projected to fall below BsAb at approximately 1.6 years (95% CI 1.3–2.3), varying from 0.8 to 3.9 years across BsAb dosing assumptions.
DISCLOSURES
Jeddeo Paul, MD, MBA: No relevant conflicts of interest to declare.